In this review, we focus on outcomes of standard therapy in TP53 mutant myeloid neoplasms, evaluate investigational therapies which have shown promise in this molecular subset, as well as provide insight into future novel combinations that will ideally finally change the natural history of this challenging disease. Here, TP53 is linked to myeloid neoplasm.